SGLT2 inhibition by empagliflozin attenuates ectopic fat accumulation and improves cardiac index in parallel to ketone bodies production: the EMPAFAT study
https://hal-amu.archives-ouvertes.fr/hal-01784725
Contributor : Monique Bernard <>
Submitted on : Thursday, May 3, 2018 - 4:57:09 PM Last modification on : Wednesday, August 19, 2020 - 12:08:20 PM
F. Maurice, P. Ancel, E. Mayoux, I. Abdesselam, F. Kober, et al.. SGLT2 inhibition by empagliflozin attenuates ectopic fat accumulation and improves cardiac index in parallel to ketone bodies production: the EMPAFAT study. 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), EASD, Sep 2017, Lisbon, Portugal. pp.S414--S414. ⟨hal-01784725⟩